STRATEC SE

Quarterly Report • Apr 29, 2015

Profile

STRATEC develops and manufactures fully automated analyzer systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. STRATEC's partners are mostly global players operating in the in-vitro diagnostics industry. These companies market STRATEC's systems under their own names, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world.

Contents

Highlights

Sales of 1 34.5 million in 3M/2015 (+0.5%; 3M/2014: 1 34.4 million)

EBIT of 1 5.8 million in 3M/2015 (+9.7%; 3M/2014: 1 5.3 million*)

EBIT margin of 16.9% in 3M/2015 (+140 basis points; 3M/2014: 15.5%*)

Earnings per share of 1 0.40 in 3M/2015 (+8.1%; 3M/2014: 1 0.37*)

Ongoing strong cash flow performance – free cash flow up 17.3% on previous year

Proposed dividend of 1 0.70 per share for 2014 (distribution in previous year: 1 0.60)

Key Group Figures at a Glance

in D thousands	01.01.-03.31.2015	01.01.-03.31.2014	Change
Sales	34,547	34,370	+0.5%
EBIT	5,840	5,326 *	+9.7%
EBIT margin (%)	16.9	15.5 *	+140 bps
Consolidated net income	4,739	4,372 *	+8.4%
Earnings per share (D)	0.40	0.37 *	+8.1%
No. of employees (03.31.)	546	546	+0.0%

in D thousands	03.31.2015	12.31.2014	Change
Shareholders' equity	120,443	112,051	+7.5%
Total assets	155,809	137,748	+13.1%
Equity ratio (%)	77.3	81.3	-400 bps

bps = basis points

* 2014 figure adjusted to exclude a one-off negative item resulting from the recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. Unadjusted EBIT amounted to 1 4.4 million; the corresponding EBIT margin amounted to 12.7%, consolidated net income to 1 3.7 million and earnings per share to 1 0.31. The actual amount of the aforementioned expense item may differ at the time of payment from the amounts presented here.

Letter from the Board of Management

Dear Shareholders,

We updated our company forecast upon the publication of our 2014 Annual Report. We continue to expect average annual sales growth of 8% to 12% through to 2017, based on 2013 sales. Within this framework, we forecast a slight rise in both sales and EBIT margin for the current 2015 financial year. These forecasts are based on the performance in the 2014 financial year, which exceeded our expectations and the anticipated increase in market launches expected in the 2016 financial year. As a result the current year will mainly be characterized by development work and the sales performance of systems already established on the market.

At the end of the first quarter of 2015, sales were broadly flat at 1 34.5 million (+0.5%) compared to the the first quarter of 2014 EBIT however grew by 9.7% to 1 5.8 million. This increase was primarily driven by efficiency enhancements, positive foreign exchange items, as well as solid performance in the spare parts and services business. Consolidated net income grew by 8.4% to 1 4.7 million, while earnings per share rose from 1 0.37 in the previous year to 1 0.40.

During the current year, we will continue our focus on achieving major milestones. These include technological developments and the conclusion of further key development and service agreements that will serve as the basis for STRATEC's growth beyond 2017. To facilitate this growth, we will be launching further construction work at various locations in the coming quarters.

Given STRATEC's continued international expansion and the increasing relevance of foreign exchange rates arising as a result, one significant topic at the company involves hedging these rates. Our primary aim here is to safeguard our revenues and holdings and ensure planning reliability.

We will be proposing the distribution of a dividend of 1 0.70 per share for the 2014 financial year for approval by the Annual General Meeting due to take place in Pforzheim on May 22, 2015. This marks the eleventh consecutive dividend increase. We aim to remain an attractive investment in a high-growth company for our shareholders, while also offering reliability in terms of our dividend distribution.

Please accept our sincere thanks for your trust.

Birkenfeld, April 2015

The Board of Management of STRATEC Biomedical AG

Marcus Wolfinger Dr. Robert Siegle Dr. Claus Vielsack

Interim Group Management Report

REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

STRATEC increased its sales by 0.5% to 1 34.5 million in the first three months of the 2015 financial year (previous year: 1 34.4 million). The gross profit (gross profit on sales) grew to 1 12.4 million (35.9% of sales), up by 1 1.2 million compared with the previous year (32.7% of sales). This growth was chiefly driven by efficiency enhancements and the solid performance of the spare parts and services business.

Gross development expenses rose by 1 0.4 million to 1 5.4 million, of which 1 3.8 million were capitalized. Sales-related expenses increased from 1 1.7 million to 1 1.9 million, while administration expenses decreased by 1 0.9 million to 1 2.5 million. This was due to the recognition in the previous year of an expense for the remaining years of the term of the employment contract with a departed member of the Board of Management.

Due to lower amortization of intangible assets, depreciation and amortization reduced from 1 2.2 million in the previous year to 1 1.1 million. At 1 5.8 million, EBIT was 1 1.5 million, or 33.7%, ahead of the previous year's figure (which included a one-off charge due to the aforementioned termination of a management board contract). This resulted in an EBIT margin of 16.9% (previous year: 12.7%). Net financial expenses amounted to 1 0.1 million (previous year: 1 -0.1 million). The tax result amounted to 1 1.2 million. STRATEC can thus report consolidated net income of 1 4.7 million for the period under report (previous year: 1 3.7 million). Earnings per share amounted to 1 0.40 (previous year: 1 0.31).

Despite strong demand for analyzer systems and a full development pipeline, it was possible to reduce inventories from 1 18.1 million in the previous year to 1 17.7 million. Due to higher trade receivables, receivables and assets rose by 1 5.0 million to 1 29.4 million.

The equity ratio amounted to 77.3%. The Group has reduced its non-current financial liabilities from 1 4.5 million to 1 4.0 million. Current financial liabilities, by contrast, grew to 1 4.5 million due to the taking up of a loan on favorable interest terms. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Alongside the marked increase in prepayments for development services, other current liabilities also include the aforementioned one-off liability for the remaining years of the term of the employment contract with a departed member of the Board of Management.

The cash flow from operating activities showed a further increase from 1 9.6 million to 1 10.1 million. At 1 1.2 million, investments fell short of the previous year's figure. Cash and cash equivalents thus increased from 1 46.6 million to 1 58.6 million as of March 31, 2015.

CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

Macroeconomic framework: In its forecast published in April 2015, the International Monetary Fund (IMF) has forecast a further slight rise in global economic growth. This will be influenced by an "unusually complex set of forces", such as the fall in the oil price and enormous shifts in currency markets.

Following growth of 3.4% in 2013 and also in 2014, the IMF now expects the global economy to grow by 3.5% this year and by 3.8% in 2016. The major economies were now better positioned than previously, while growth in the developing and emerging economies had lost some of its momentum.

Given the implications of the euro debt crisis, by contrast, the IMF believes that the euro area faces a longer-term period of weak economic growth. For 2015, the IMF has nevertheless raised its forecast for the euro area from 1.2% to 1.5%. Growth in the coming year should then amount to 1.6%. In 2014, economic output grew by a mere 0.9%, while one year earlier the currency area was still in recession. Like other major economic regions, the euro area had also profited greatly in recent months from the low oil price. According to the IMF, the interest rate cuts by the European Central Bank and increased strength of the US dollar would also impact positively. Unemployment was set to fall across almost the entire euro area.

One aspect that concerns the IMF is the possibility of a further sharp appreciation in the US dollar, which could trigger financial tensions in emerging economies in particular. Furthermore, the consequences of low interest rates, which have led to an enormous upturn in stock and real estate markets, could become a threat to stability.

Irrespective of the aforementioned developments, global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications for STRATEC.

Industry and market data: Based on different estimates, in-vitro diagnostics (IVD) will continue to show average global growth of around 4% to 5% in the years until 2018 and 2020 respectively. Some regions, such as the BRIC states, are growing significantly faster, while other regions, such as Europe, are not expected to show any growth. Similar developments can be seen in the various IVD segments. While some areas in which STRATEC consciously does not operate, such as blood sugar self-testing, are expected to decline significantly, other segments are expected to show very strong growth in future as well. STRATEC plans to continue benefiting to a disproportionate extent from these growth rates by deliberately tracking down and developing projects in high-growth niches. The company currently has both customer projects and proprietary platform solutions in development for several of these sub-segments.

The US still represent a special case. While cost savings could have a slightly negative impact on the test volumes handled at laboratories, overall test volumes are nevertheless expected to rise due to the growing number of people with health insurance. On the one hand, the number of people insured has most recently risen slightly due to lower unemployment rates and is expected to remain stable until 2018. On the other hand the Affordable Care Act (Obamacare) is expected to substantially increase the number of people insured from around 217 million in 2015 to around 235 million, unless Obamacare is blocked or restricted by court decisions.

Even though the diagnostics, pharmaceuticals and healthcare industry repeatedly witnesses short-term periods of consolidation at individual market players due to corporate takeovers and new technological development possibilities, several underlying factors will guarantee sustainable growth in future as well:

• Increasing market regulation, leading manual and semi-automated, in some cases homegrown test methods to be displaced by fully automated processes – whose lifecycles are thus simultaneously extended
• Development and expansion in healthcare systems, particularly in developing and emerging economies (especially in BRIC states)
• Expansion in global infrastructure and thus improved access to medical care
• Rapidly growing niche markets due to new medical discoveries and new diagnostic possibilities
• Newly developed diagnostics tests in all major areas of application, such as for oncology, sexually transmitted diseases, or hospital bugs
• Demographic developments (growing global population, increasingly elderly population with growing diagnostics requirements).

report on forecasts and other statements concerning the company's expected development

STRATEC aims to generate permanent, sustainable growth in all business divisions. We are building on innovative solutions enabling our customers to serve their markets with high-quality products. Alongside the activities within our group of companies, we are also relying on further growth in our target markets, especially in the field of in-vitro diagnostics and on the continuing positive trend towards outsourcing at our partners and potential customers.

STRATEC published its currently valid company forecast on July 12, 2013. This forecasts average annual growth of between 8% and 12% through to 2017 on the basis of 2013 sales (1 128 million). Growth rates may fluctuate significantly in individual years and quarters and thus leave the target corridor in individual reporting periods. The overall forecast through to 2017 should nevertheless remain intact. This forecast remains valid for the overall period. The highly transparent forecasts provided by our customers enable us to issue forecasts with a high degree of security, but also reveal potential upward and downward deviations from forecast developments in individual periods.

For the current 2015 financial year, STRATEC expects to be able to generate slight sales growth accompanied by a slight increase in its EBIT margin. Due to expected and planned market launches, among other factors, the company expects to generate substantial sales growth once again in 2016.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), movements in currency markets, and volatile developments in individual economic regions, the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 31, 2015 upon the compilation of the Annual Report for the 2014 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

opportunity and risk report

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2014 financial year dated March 31, 2015. Details of our risk management system and our company's specific opportunity and risk profile can be found in Section D "Opportunity and Risk Report" of our 2014 Group Management Report. Information about our use of financial instruments can be found in Section F of the 2014 Group Management Report.

Consolidated Balance Sheet

as of March 31, 2015 of STRATEC Biomedical AG

Assets in D thousands	03.31.2015	12.31.2014
Non-current Assets
Goodwill	5,166	4,785
Other intangible assets	25,893	25,477
Property, plant and equipment	16,572	15,954
Interests in associates	184	263
Deferred tax assets	1,367	1,260
	49,182	47,739
Current Assets
Raw materials and supplies	8,979	8,065
Unfinished products, unfinished services	6,985	6,591
Finished products and goods	1,766	3,410
Trade receivables	23,723	18,961
Future receivables from construction contracts	868	1,644
Receivables from associates	21	23
Income tax receivables	3,171	2,635
Other receivables and other assets	1,602	1,167
Other financial assets	949	877
Cash and cash equivalents	58,563	46,636
	106,627	90,009
Total Assets	155,809	137,748

Shareholders' Equity and Debt in D thousands	03.31.2015	12.31.2014
Shareholders' equity
Share capital	11,795	11,795
Capital reserve	18,166	18,129
Revenue reserves	85,210	80,478
Other equity	5,272	1,649
	120,443	112,051
Debt
Non-current Debt
Non-current financial liabilities	4,031	4,484
Pension provisions	61	61
Deferred taxes	6,336	5,565
	10,428	10,110
Current Debt
Current financial liabilities	4,491	2,449
Trade payables	5,016	2,814
Liabilities to associates	39	41
Other current liabilities	11,958	7,140
Current provisions	1,885	1,732
Income tax liabilities	1,549	1,411
	24,938	15,587
Total Shareholders' Equity and Debt	155,809	137,748

Consolidated Statement of Comprehensive Income

for the Period from January 1 to March 31, 2015 of STRATEC Biomedical AG

in D thousands	01.01.-03.31.2015	01.01.-03.31.2014
Sales	34,547	34,370
Cost of sales	-22,128	-23,139
Gross profit	12,419	11,231
Research and development expenses	-1,556	-1,402
Information only: Total research and development expenses	-5,382	-4,950
Information only: Capitalized research and development expenses	3,826	3,548
Sales-related expenses	-1,890	-1,675
General administrative expenses	-2,597	-3,508
Other operating income and expenses	-536	-278
EBIT	5,840	4,368
Net financial expenses	72	-82
Earnings before taxes (EBT)	5,912	4,286
Current tax expenses	-584	-455
Deferred tax expenses	-589	-170
Consolidated net income	4,739	3,661
Items that may be subsequently reclassified to profit or loss
Currency translation differences from translation of foreign operations	3,623	154
Comprehensive income	8,362	3,815
Earnings per share in 3	0.40	0.31
No. of shares used as basis	11,783,222	11,758,022
Earnings per share, diluted, in 3	0.40	0.31
No. of shares used as basis, diluted	11,869,907	11,778,667

Consolidated Cash Flow Statement

for the Period from January 1 to March 31, 2015 of STRATEC Biomedical AG

in D thousands	01.01.-03.31.2015	01.01.-03.31.2014
Consolidated net income (after taxes)	4,739	3,661
Depreciation and amortization	1,075	2,189
Current income tax expenses	584	455
Income taxes paid less income taxes received	-1,105	-1,337
Financial income	-44	-9
Financial expenses	44	51
Interest paid	-52	-51
Interest received	74	8
Other non-cash expenses	532	210
Other non-cash income	-227	-132
Cash flow	5,620	5,045
Change in deferred taxes through profit or loss	589	170
Increase in inventories, trade receivables and other assets	-2,858	-1,221
Increase in trade payables and other liabilities	6,768	5,597
Inflow of funds from operating activities	10,119	9,591
Incoming payments from disposals of non-current assets
Property, plant and equipment	6	0
Outgoing payments for investments in non-current assets
Intangible assets	-774	-1,592
Property, plant and equipment	-395	-362
Outflow of funds for investing activities	-1,163	-1,954
Incoming payments from taking up of financial liabilities	2,000	0
Outgoing payments for repayment of financial liabilities	-721	-690
Inflow (previous year: outflow) of funds for financing activities	1,279	-690
Cash-effective change in cash and cash equivalents	10,235	6,947
Cash and cash equivalents at start of period	46,636	20,734
Change in scope of consolidation	79	0
Impact of exchange rate movements	1,613	37
Cash and cash equivalents at end of period	58,563	27,718

Consolidated Statement of Changes in Equity

for the Period from January 1 to March 31, 2014 of STRATEC Biomedical AG

in D thousands	Share capital	Capital reserve
Balance at 01.01.2014	11,770	17,219
Allocations due to stock option plans		111
Total comprehensive income
Balance at 03.31.2014	11,770	17,330

for the Period from January 1 to March 31, 2015 of STRATEC Biomedical AG

in D thousands	Share capital	Capital reserve
Balance at 01.01.2015	11,795	18,129
Allocations due to stock option plans		37
Total comprehensive income
Change in scope of consolidation
Balance at 03.31.2015	11,795	18,166

Other equity					Revenue reserves
Pension plans	Treasury stock	Free revenue reserves	Accumulated net income
-18	-212	19,392	48,374
			3,661
-32	-212	19,392	52,035

Revenue reserves			Other equity
Accumulated net income	Free revenue reserves	Treasury stock	Pension plans	Currency translation	Group equity
61,086	19,392	-212	-67	1,928	112,051
					37
4,739				3,623	8,362
-7
65,818	19,392	-212	-67	5,551	120,443

Notes to the Group Interim Report

for the Period from January 1 to March 31, 2015 of STRATEC Biomedical AG

Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2014 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of March 31, 2015, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2014 financial year. One exception applies to the first-time inclusion in the scope of consolidation of STRATEC Services AG, Beringen, Switzerland, a company founded in the 2014 financial year. The implications of the first-time full consolidation of this company for the net asset, financial and earnings position of the STRATEC Group are of subordinate significance. Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of March 31, 2015.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2014 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (1 thousand).

Segment disclosures

Apart from the first-time inclusion of STRATEC Services AG, Beringen, Switzerland, in the "Instrumentation" segment, there have been no changes in segmentation compared with the consolidated financial statements as of December 31, 2014.

Segment data by operating segment for the period from January 1 to March 31, 2015

in D thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	35,781	2,799	-4,033	34,547
EBIT	5,832	215	-207	5,840
Assets	167,837	7,412	-19,440	155,809

Segment data by operating segment for the period from January 1 to March 31, 2014

in D thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	35,330	1,885	-2,845	34,370
EBIT	4,244	199	-75	4,368
Assets	136,294	7,000	-16,285	127,009

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in D thousands	Germany	EU	Other	Total
	6,125	13,237	15,185	34,547
January - March 2015	17.7%	38.3%	44.0%	100.0%

in D thousands	Germany	EU	Other	Total
	4,055	15,815	14,500	34,370
January - March 2014	11.8%	46.0%	42.2%	100.0%

Research and development expenses

Research and development expenses not fulfilling the capitalization criteria set out in IAS 38 (Intangible Assets) amounted to 1 1.6 million in the first three months of the 2015 financial year (previous year: 1 1.4 million) and mainly involve personnel and material expenses. The STRATEC Group invested a total of 1 5.4 million in research and development in the first three months of the 2015 financial year (previous year: 1 5.0 million). Due to the modification in the recognition of gross development expenses in the statement of comprehensive income at the end of the 2014 financial year, the comparative figures in the interim report have also been adjusted accordingly.

Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 13 and 14.

The number of ordinary shares with a nominal value of D 1.00 each issued by STRATEC Biomedical AG as of March 31, 2015, amounts to 11,795,445. These are all bearer shares.

Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC Biomedical AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of 1 12,223.00 of the company's share capital and to a 0.10% share of its equity.

Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

in D thousands	Board of Management/ Managing Directors	Employees	Total
Outstanding on 01.01.2015	171,000	99,500	270,500
Issued	0	2,300	2,300
Exercised	0	0	0
Lapsed	0	0	0
Forfeited	0	0	0
Outstanding on 03.31.2015	171,000	101,800	272,800

A total of 2,300 stock option rights were granted to company employees on the basis of option agreements dated February 1, 2015.

Employees

Including temporary employees the STRATEC Group had a total workforce of 546 employees as of March 31, 2015 (previous year: 546).

Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

Additional Information

Financial Calendar

April 29, 2015	Interim Report as of March 31, 2015
May 22, 2015	Annual General Meeting, Pforzheim, Germany
July 23, 2015	Interim Report as of June 30, 2015
October 28, 2015	Interim Report as of September 30, 2015
November 2015	German Equity Forum, Frankfurt/Main, Germany – Analysts' conference –

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2015:

May 2015	Deutsche Bank – 40th Annual Health Care Conference, Boston, USA Berenberg Diagnostics Conference, London, UK UBS Pan European small & midcap Conference, London, UK Berenberg European Conference, Tarrytown, USA
June 2015	Jefferies 2015 Global Healthcare Conference, New York City, USA
September 2015	Commerzbank Sector Conference, Frankfurt / Main, Germany 12th Annual Goldman Sachs European Medtech and Healthcare Services Conference, London, UK Berenberg Bank & Goldman Sachs German Corporate Conference, Munich, Germany
November 2015	HSBC Healthcare Day 2015, Frankfurt / Main, Germany
December 2015	Berenberg Bank European Conference, Pennyhill Park, UK

Partially incomplete/subject to amendment

About STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at www.stratec.com.

Imprint

Published by

STRATEC Biomedical AG Gewerbestr, 37 75217 Birkenfeld Germany

Investor Relations

Andreas Künzel Phone: +49 7082 7916-185 Fax: +49 7082 7916-999 a.kuenzel@stratec.com

Phone: +49 7082 7916-0 Fax: +49 7082 7916-999 info@stratec.com www.stratec.com

Corporate Communications

Andre Loy Phone: +49 7082 7916-190 Fax: +49 7082 7916-999 a.loy@stratec.com

Concept and Design Whitepark GmbH & Co., Hamburg, Germany Text STRATEC Biomedical AG, Birkenfeld, Germany

NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

STRATEC Biomedical AG

Gewerbestr. 37 75217 Birkenfeld Germany

Phone: +49 7082 7916-0 Fax: +49 7082 7916-999

info@stratec.com www.stratec.com